HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2
- PMID: 8954611
- DOI: 10.1006/cimm.1996.0301
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2
Abstract
This study was carried out to determine whether HLA class I or class II expression on ovarian tumor cells and lymphocytic infiltration of the epithelial ovarian carcinoma (EOC) tissues were responsible for the ability to expand tumor-infiltrating lymphocytes (TIL) in vitro in low concentrations of recombinant interleukin-2 (rIL-2). Immunohistochemical analysis was performed using monoclonal antibodies that recognize framework determinants of either HLA class I or HLA class II or leukocyte differentiation antigens (LCA, CD3, CD4, and CD8). Cryostat sections of EOC had HLA class I and HLA class II expression on at least 5% of tumor cells in 18 of 20 specimens (90%). From another portion of the same tumor specimens T-cell lines were developed from TIL in low concentrations of rIL-2 (200-600 IU/ml) in 7 of 17 patients. Tumors from which TIL were expanded in vitro with rIL-2 had significantly higher proportions of HLA class I-positive tumor cells (73 +/- 10%) compared to tumors from which TIL failed to grow (40 +/- 10%) (P = 0.036). However, there was no difference in the proportions of HLA class II-positive tumor cells between the two groups. Tumor specimens of patients whose TIL were expanded in rIL-2 had significantly higher numbers per field (423 +/- 114 vs 154 +/- 20; P = 0.005) and proportions (90 +/- 3% vs 77 +/- 4%; P = 0.023) of infiltrating CD3+ cells, significantly higher numbers per field (115 +/- 44 vs 19 +/- 5; P = 0.003) and proportions (25 +/- 5% vs 11 +/- 2%; P = 0.017) of CD8+ cells and significantly higher numbers per field of CD4+ cells (318 +/- 101 vs 113 +/- 18; P = 0.025), in comparison to tumor specimens from patients whose TIL did not grow in vitro. Significant correlations were observed between the proportions of HLA class I-positive EOC tumor cells and the numbers of infiltrating LCA-positive cells (r = 0.67; P = 0.005) CD3+ cells (r = 0.70; P = 0.002), CD4+ cells (r = 0.69; P = 0.003), and CD8+ cells (r = 0.82; P = 0.001). The proportions of HLA class II-positive tumor cells correlated positively (r = 0.45; P = 0.049) only with the numbers of CD8+-infiltrating cells. In conclusion, we report here that HLA class I expression on EOC cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro, in low concentrations of rIL-2.
Similar articles
-
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.Clin Cancer Res. 2000 Jun;6(6):2268-78. Clin Cancer Res. 2000. PMID: 10873077 Clinical Trial.
-
Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.Gynecol Oncol. 2001 Jun;81(3):424-32. doi: 10.1006/gyno.2001.6200. Gynecol Oncol. 2001. PMID: 11371133
-
Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes.Eur J Immunol. 1992 Jul;22(7):1795-802. doi: 10.1002/eji.1830220719. Eur J Immunol. 1992. PMID: 1623924
-
Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.Cancer Treat Res. 1996;82:115-46. doi: 10.1007/978-1-4613-1247-5_8. Cancer Treat Res. 1996. PMID: 8849947 Review.
-
The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors.Immunol Res. 1995;14(2):119-31. doi: 10.1007/BF02918172. Immunol Res. 1995. PMID: 8530876 Review.
Cited by
-
Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.J Transl Med. 2014 May 9;12:119. doi: 10.1186/1479-5876-12-119. J Transl Med. 2014. PMID: 24885819 Free PMC article. Clinical Trial.
-
Cancer Vaccines in Ovarian Cancer: How Can We Improve?Biomedicines. 2016 May 3;4(2):10. doi: 10.3390/biomedicines4020010. Biomedicines. 2016. PMID: 28536377 Free PMC article. Review.
-
Monocyte and interferon based therapy for the treatment of ovarian cancer.Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15. Cytokine Growth Factor Rev. 2016. PMID: 27026228 Free PMC article.
-
The current status of immunobased therapies for metastatic renal-cell carcinoma.Immunotargets Ther. 2017 Dec 5;6:83-93. doi: 10.2147/ITT.S134850. eCollection 2017. Immunotargets Ther. 2017. PMID: 29255699 Free PMC article. Review.
-
The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis.Cell Signal. 2019 Aug;60:39-56. doi: 10.1016/j.cellsig.2019.03.024. Epub 2019 Apr 2. Cell Signal. 2019. PMID: 30951861 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials